Samantha Semenkow
Stock Analyst at Citi
(0.84)
# 4,039
Out of 5,023 analysts
217
Total ratings
42%
Success rate
-1.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Samantha Semenkow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTR Nektar Therapeutics | Maintained: Buy | $151 | $68.50 | +120.44% | 12 | Oct 5, 2026 | |
| BIOA BioAge Labs | Maintained: Buy | $21 | $8.48 | +147.64% | 12 | Sep 29, 2026 | |
| CGEM Cullinan Therapeutics | Maintained: Buy | $33 | $20.40 | +61.76% | 5 | Sep 25, 2026 | |
| BHVN Biohaven | Maintained: Buy | $17 | $12.64 | +34.49% | 7 | Sep 18, 2026 | |
| DNTH Dianthus Therapeutics | Initiated Coverage: Buy | $156 | $107.69 | +44.86% | 1 | Sep 4, 2026 | |
| CABA Cabaletta Bio | Reiterated: Buy | $10 | $2.91 | +243.64% | 12 | Sep 1, 2026 | |
| ARGX argenx SE | Reiterated: Buy | $1,203 → $1,301 | $990.54 | +31.34% | 21 | Aug 18, 2026 | |
| GPCR Structure Therapeutics | Reiterated: Buy | $97 | $38.44 | +152.34% | 7 | Aug 10, 2026 | |
| ROIV Roivant Sciences | Reiterated: Buy | $42 → $46 | $41.02 | +12.14% | 6 | Aug 10, 2026 | |
| RYTM Rhythm Pharmaceuticals | Reiterated: Buy | $142 → $143 | $102.44 | +39.59% | 3 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $46 → $52 | $33.22 | +56.53% | 5 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 → $19 | $4.58 | +314.85% | 5 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $57 → $61 | $37.66 | +61.98% | 16 | Jun 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $3.78 | +270.37% | 19 | Jun 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $3.46 | +217.92% | 2 | Jun 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $68 | $24.12 | +181.92% | 15 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $64 → $97 | $90.80 | +6.83% | 3 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $4 | $1.78 | +124.72% | 6 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $3.19 | +244.83% | 6 | Mar 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $6 | $12.68 | -52.68% | 9 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $3.20 | +275.00% | 14 | Mar 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5 → $4.25 | $3.18 | +33.65% | 8 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 → $5 | $2.74 | n/a | 9 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $6 → $4 | $39.09 | n/a | 8 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1.7 → $0.75 | $0.000001 | n/a | 3 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $130 | $24.58 | n/a | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 → $7 | $3.52 | n/a | 2 | Jul 21, 2021 |
Nektar Therapeutics
Oct 5, 2026
Maintained: Buy
Price Target: $151
Current: $68.50
Upside: +120.44%
BioAge Labs
Sep 29, 2026
Maintained: Buy
Price Target: $21
Current: $8.48
Upside: +147.64%
Cullinan Therapeutics
Sep 25, 2026
Maintained: Buy
Price Target: $33
Current: $20.40
Upside: +61.76%
Biohaven
Sep 18, 2026
Maintained: Buy
Price Target: $17
Current: $12.64
Upside: +34.49%
Dianthus Therapeutics
Sep 4, 2026
Initiated Coverage: Buy
Price Target: $156
Current: $107.69
Upside: +44.86%
Cabaletta Bio
Sep 1, 2026
Reiterated: Buy
Price Target: $10
Current: $2.91
Upside: +243.64%
argenx SE
Aug 18, 2026
Reiterated: Buy
Price Target: $1,203 → $1,301
Current: $990.54
Upside: +31.34%
Structure Therapeutics
Aug 10, 2026
Reiterated: Buy
Price Target: $97
Current: $38.44
Upside: +152.34%
Roivant Sciences
Aug 10, 2026
Reiterated: Buy
Price Target: $42 → $46
Current: $41.02
Upside: +12.14%
Rhythm Pharmaceuticals
Aug 5, 2026
Reiterated: Buy
Price Target: $142 → $143
Current: $102.44
Upside: +39.59%
Jul 31, 2026
Reiterated: Buy
Price Target: $46 → $52
Current: $33.22
Upside: +56.53%
Jul 31, 2026
Reiterated: Buy
Price Target: $24 → $19
Current: $4.58
Upside: +314.85%
Jun 30, 2026
Reiterated: Buy
Price Target: $57 → $61
Current: $37.66
Upside: +61.98%
Jun 30, 2026
Reiterated: Buy
Price Target: $14
Current: $3.78
Upside: +270.37%
Jun 15, 2026
Reiterated: Buy
Price Target: $11
Current: $3.46
Upside: +217.92%
May 13, 2026
Reiterated: Buy
Price Target: $68
Current: $24.12
Upside: +181.92%
May 6, 2026
Rated: Buy
Price Target: $64 → $97
Current: $90.80
Upside: +6.83%
Apr 9, 2026
Rated: Buy
Price Target: $4
Current: $1.78
Upside: +124.72%
Mar 23, 2026
Reiterated: Buy
Price Target: $11
Current: $3.19
Upside: +244.83%
Mar 20, 2026
Reiterated: Sell
Price Target: $6
Current: $12.68
Upside: -52.68%
Mar 4, 2026
Reiterated: Buy
Price Target: $12
Current: $3.20
Upside: +275.00%
Nov 11, 2025
Reiterated: Hold
Price Target: $5 → $4.25
Current: $3.18
Upside: +33.65%
Mar 6, 2025
Reiterated: Buy
Price Target: $15 → $5
Current: $2.74
Upside: n/a
Jun 3, 2024
Initiated Coverage: Buy
Price Target: $6 → $4
Current: $39.09
Upside: n/a
May 18, 2023
Reiterated: Hold
Price Target: $1.7 → $0.75
Current: $0.000001
Upside: n/a
May 11, 2023
Rated: Buy
Price Target: $130
Current: $24.58
Upside: n/a
Jul 21, 2021
Reiterated: Buy
Price Target: $16 → $7
Current: $3.52
Upside: n/a